Hannah Brendan 4

What Happened
Hannah Brendan, Quince Therapeutics’ Chief Business Officer, Chief Operating Officer and Chief Commercial Officer, was granted 365,000 derivative shares/options on January 23, 2026. The grant is reported at $0.00 (no cash paid at grant). This is a compensation award (not an open-market purchase or sale) and does not represent an immediate sale or exercise.

Key Details

• Transaction date: 2026-01-23; Form 4 filed 2026-01-23 (timely filing).
• Transaction type/code: A — Grant/Award (derivative).
• Shares granted: 365,000; reported price: $0.00 (no cash exchanged at grant).
• Shares owned after transaction: not specified in the provided summary of the filing.
• Footnote (vesting): The award vests in equal monthly installments of 1/48th of the total, with 1/48th vesting on the grant date and the remainder vesting on the 1st day of each subsequent month, fully vested on December 1, 2029.

Context
This is a standard executive compensation grant subject to a multi-year vesting schedule. Because it is an award (not a purchase or sale), it should be viewed as part of routine compensation rather than a direct signal of insider buying or selling. The award will only translate into freely tradable shares as portions vest or if and when any options are exercised per plan terms.